Monte Rosa Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
85.2M
on 2026-06-30, from 50.2M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-02-11. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗
$100.0M
Jefferies, agreement of 2026-02-11. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-06 is not read yet.
Cash
15 quarters
$90.1M on 2026-06-30 ÷ $6.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-01-08 | Public offering incl. 1.38M pre-funded | 12,500,000 | $24.00 | $300.0M | 424B5 ↗ |